

Form PTO-1449 (modified)		Atty. Docket No.: SONN:076US	Serial No.: 10/550,754
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Michael Buschle <i>et al.</i>	
		Filing Date: September 23, 2005	Group: 1648
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C90	Aichinger <i>et al.</i> , "Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins," <i>J. Biol. Chem.</i> , 272:29127-29136, 1997.
	C91	Bihl <i>et al.</i> , "Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses," <i>J. Immunol.</i> , 176:4094-4101, 2006.
	C92	Brooks <i>et al.</i> , "HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex," <i>J. Immunol.</i> , 161:5252-5259, 1998.
	C93	Field, "Human cytomegalovirus: challenges, opportunities and new drug development," <i>Antiviral Chem. Chemotherapy</i> , 10:219-232, 1999.
	C94	Fowler <i>et al.</i> , "The outcome of congenital cytomegalovirus infection in relation to maternal antibody status," <i>New Engl. J. Med.</i> , 326:663-673, 1992.
	C95	Gallot <i>et al.</i> , "Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination," <i>J. Immunol.</i> , 167:4196-4206, 2001.
	C96	Gavin <i>et al.</i> , "Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes," <i>J. Immunol.</i> , 151:3971-3980, 1993.

25775707.1

EXAMINER: /E.L./

DATE CONSIDERED: 06/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No.: SONN:076US	Serial No.: 10/550,754
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Michael Buschle <i>et al.</i>	
		Filing Date: September 23, 2005	Group: 1648
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C97	Gorga <i>et al.</i> , "Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line," <i>J. Biol. Chem.</i> , 262:16087-16094, 1987.
	C98	Greenberg and Riddell, "Deficient Cellular Immunity- Finding and Fixing the Defects," <i>Science</i> , 285:546-551, 1999.
	C99	Khattab <i>et al.</i> , "Three T-cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes," <i>J. Med. Virol.</i> , 52:68-76, 1997.
	C100	Kronenberg <i>et al.</i> , "Conserved lipid and peptide presentation functions of nonclassical class I molecules," <i>Immunol. Today</i> , 20:515-521, 1999.
	C101	Kuzushima <i>et al.</i> , "Efficient Identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay," <i>Blood</i> , 98:1872-1880, 2001.
	C102	Lalvani <i>et al.</i> , "Rapid effector function in CD8+ memory T cells," <i>J. Exp. Med.</i> , 186:859-865, 1997.
	C103	Lamas <i>et al.</i> , "Relationship between peptide binding and T cell epitope selection: a study with subtypes of HLA-B27," <i>Int. Immunol.</i> , 10:259-266, 1998.
	C104	Levitsky <i>et al.</i> , "Supermotif Peptide Binding and Degeneracy of MHC: Peptide Recognition in an EBV Peptide-Specific CTL Response with Highly Restricted TCR Usage," <i>Human Immunol.</i> , 61:972-984, 2000.
	C105	Masuoka <i>et al.</i> , "Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes," <i>Viral Immunology</i> , 14:369-377, 2001.
	C106	McLaughlin-Taylor <i>et al.</i> , "Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes," <i>J. Med. Virol.</i> , 43:103-110, 1994.
	C107	Nichols and Boeckh, "Recent advances in the therapy and prevention of CMV infections," <i>J. Clin. Virol.</i> , 16:25-40, 2000.
	C108	Nijman <i>et al.</i> , "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> , 6:1215-1219, 1993.

25775707.1

EXAMINER: /E.L./

DATE CONSIDERED: 06/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No.: SONN:076US	Serial No.: 10/550,754
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Michael Buschle <i>et al.</i>	
		Filing Date: September 23, 2005	Group: 1648
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C109	Retriere <i>et al.</i> , "Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response," <i>J. Virol.</i> , 74:3948-3952, 2000.
	C110	Saulquin <i>et al.</i> , "A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening," <i>Eur. J. Immunol.</i> , 30:2531-2539, 2000.
	C111	Sia and Patel, "New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients," <i>Clin. Microbiol. Rev.</i> , 13:83-121, 2000.
	C112	Solache <i>et al.</i> , "Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus," <i>J. Immunol.</i> , 163:5512-5518, 1999.
	C113	Tynan <i>et al.</i> , "The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation," <i>J. Exp. Med.</i> , 202:1249-1260, 2005.
	C114	Udaka <i>et al.</i> , "Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries," <i>J. Exp. Med.</i> , 181:2097-2108, 1995.
	C115	Valli <i>et al.</i> , "Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients," <i>J. Clin. Invest.</i> , 91:616-628, 1993.
	C116	Von Son <i>et al.</i> , "Overcoming the problem of cytomegalovirus infection after organ transplantation: calling for Heracles?," <i>Intervirology</i> , 42:285-290, 1999.

25775707.1

EXAMINER: /Emily Le/

DATE CONSIDERED: 06/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./